Clinical Trial Update: Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib with or without bevacizumab in EGFR-positive non-small cell lung cancer with brain metastases; results were posted on 2026-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• TAGRISSO (osimertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-17